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1. Introduction
The non-Alzheimer dementias (NAD) are a group of disorders that account for approxi‐
mately 30 to 40 per cent of dementias worldwide [1-3]. Some of the common types of NAD
are listed in Table 1.
2. Vascular dementia
The term vascular dementia (VaD) deals with cognitive impairment affecting daily activities
required for living of vascular origin (ischemia, haemorrhage). However, VaD as a concept
and disease entity is undergoing regular transformation. The term ‘vascular cognitive im‐
pairment’ (VCI) introduced in 1995 [4] is used to include any cognitive impairment from
cerebrovascular disease (CVD) except major stroke. It was then proposed that the term VCI
should include all forms of cognitive impairment associated with CVD [5] (Table 2). This
term would include not only VaD but also mild cognitive impairment (MCI) with no de‐
mentia and dementia of mixed origin (Alzheimer’s and vascular dementia) (see [6]). It has
been argued that this classification does not fit the purpose of clinical differentiation and
that this term should be restricted to MCI without dementia due to vascular cause [7]. How‐
ever, some scholars are of the opinion that VCI is a research terminology and that clinicians
should identify the condition and deal with the associated risk factors thereby avoiding pro‐
gression to VaD [8].
The diagnostic criteria that characterise cognitive syndromes associated with vascular dis‐
ease are usually based on two factors: demonstration of presence of a cognitive disorder by
neuropsychological testing and history of clinical stroke or presence of vascular disease by
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neuroimaging that suggests a link between the cognitive disorder and vascular disease. The
term VCI is not used for patients who have an active diagnosis of drug or alcohol depend‐
ence or for patients with delirium [9].
2.1. Epidemiology
VaD is considered to be the second most prevalent type of dementia worldwide accounting
for about 15 to 20 % of the dementia cases [10]. Prevalence of VaD in Japan has been report‐
ed to be as high as 47 % [11]. 16 % of all cases of late-onset dementia (65 years or after) [12]
and 18 % of all cases of early-onset dementia (below 65 years) [13] was found to be VaD.
However, it must be kept in mind that establishing the exact epidemiology of VaD is not an
easy task mainly due to difficulty in diagnosing clinically [14] and overlap of AD neuropa‐
thology (see [15]).
Some of the risk factors for developing VaD are hypertension [16] and metabolic factors like
diabetes and obesity. Males are considered to be at a significantly higher risk of developing
VaD [17]. The incidence rate of VaD was found to be two times higher than Alzheimer’s dis‐
ease for males in Japan [18]. The risk factors have been classified [19] and are listed in Table
3. Some of the protective factors found in the Canadian Study of Health and Aging include
eating shellfish and regular exercise for women [20]. Antioxidants, which include vitamin E
and C and also intake of fatty fish have been found to be protective against VCI [21].
a. Vascular dementia
• Vascular dementia of acute onset (post-stroke)
• Multi-infarct dementia
• Subcortical vascular dementia (Binswanger’s disease)
• Mixed cortical and subcortical vascular dementia
• Other vascular dementia (CADASIL, vasculitis, post-cardiac arrest)
b. Dementia with Lewy Bodies
c. Frontotemporal dementia
d. Dementia in other diseases
• Pick’s disease
• Creutzfeldt-Jakob disease
• Huntington’s disease
• Parkinson’s disease
• Human immunodeficiency virus (HIV) disease
e. Treatable or reversible dementias
• Normal pressure hydrocephalus
• Alcohol-related
• Neoplasia (glioma, meningioma, secondaries)
• Vitamin deficiencies (B12, folate, thiamine, nicotinic acid)
• Metabolic and endocrine (liver disease, hypothyroidism)
Table 1. Types of non-Alzheimer dementia
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• VCI-no dementia
• Vascular dementia
• Mixed Alzheimer’s disease and vascular dementia
Table 2. Vascular cognitive impairment (VCI)
1. Demographic
Age
Male sex
Lower educational level
2. Atherosclerosis
Hypertension
Cigarette smoking
Myocardial infarction
Diabetes mellitus
Hyperlipidemia
3. Genetic
CADASIL
Apolipoprotein E
4. Stroke-related
Volume of cerebral tissue loss
Bilateral cerebral infarction
Strategic infarction (thalamic, angular gyrus)
White matter disease
Table 3. Risk factors for vascular dementia according to reference [18]
2.2. Clinical features and pathophysiology
Firstly, to diagnose dementia, there should be a decline in memory and a decline in at least
two cognitive skills such as orientation, social behaviour, verbal skills, attention, motor con‐
trol, praxis, emotional control and executive functions (goal-directed behaviour and prob‐
lem-solving skills). In VaD, the onset may be sudden or gradual, with stepwise progression.
Since vascular component is involved, there may be focal neurological deficits such as hemi‐
paresis or swallowing disturbances and dysarthria (pseudobulbar lesion symptoms). A his‐
tory of transient ischaemic attacks is common. Depending on the site of the lesion, features
such as motor aphasia, dyspraxia (due to left anterior cerebral artery ischemia) or psychosis
(right middle cerebral artery) or amnesia and visual disturbances (posterior cerebral artery)
may be seen. Other important associated features include gait disturbance which may be as‐
sociated with a history of unsteadiness as well as frequent falls. It is vital to distinguish de‐
mentia of vascular origin from degenerative form of dementia. This is because VaD, when
diagnosed at an early stage provides for chances to prevent or delay progression. Thus,
treatment strategies may vary. For this purpose, clinicians use a scoring system called Ha‐
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chinski ischaemic score [22]. A score of above six signifies dementia due to vascular cause.
Some of the clinical criteria developed to assist in diagnosing VaD include State of Califor‐
nia Alzheimer Disease Diagnostic and Treatment Centers (ADDTC) criteria [23], Interna‐
tional Classification of Diseases (ICD-10) criteria [24], National Institute of Neurological
Disorders and Stroke (NINDS)-Association Internationale pour la Recherche et l'Enseigne‐
ment en Neurosciences (AIREN) criteria [25] and Diagnostic and Statistical Manual for Men‐
tal Disorders (DSM-IV) criteria [26].
The most  widely followed or  accepted criteria  for  diagnosis  of  VaD is  the NINDS-AIR‐
EN  criteria.  According  to  this,  both  clinical  and  radiological  criteria  must  be  fulfilled.
Clinical criteria include presence of dementia and CVD as well as a relation between the
two features i.e. dementia should develop after and within 3 months of the stroke. Radi‐
ological  criteria are based on topography and severity of  vascular lesions.  There should
be either a large vessel stroke or multiple lacunar infarcts in basal ganglia or white mat‐
ter lesions in periventricular regions. Large vessel lesions should be present in dominant
hemisphere or in both the hemispheres while white matter lesions must involve at least
25 % of the cerebral white matter. However it  was found that the neuroimaging criteria
listed above does not always differentiate between stroke patients with and without de‐
mentia  [27].  Definite  vascular  dementia  is  diagnosed  by  fulfilling  the  above  mentioned
criteria  with histopathological  evidence from brain biopsy or  autopsy.  Absence of  other
causes of dementia must be ruled out.
2.2.1. Post-stroke dementia
Post-stroke dementia (PSD) is the type of VaD developing after a stroke. Among patients
who have experienced a first stroke, the prevalence of poststroke dementia (PSD) varies in
relation to the interval after stroke, definition of dementia, location and size of the infarct.
This includes a large-vessel lesion or single strategic lesion (thalamus or midbrain) (Figure
1). The cause of stroke may be haemorrhagic, or ischemic. The rate of dementia in people
with stroke was found to be two times respect people without stroke [28]. Increasing age is
significantly associated with PSD [29,30]. The severity of cognitive decline after a stroke is
associated with increased risk of PSD [31]. Long-term mortality is 2 to 6 times higher in pa‐
tients with PSD after adjustment for demographic factors, associated cardiac diseases, stroke
severity, and stroke recurrence (for review, see [32]). Silent cerebral infarcts, white matter
changes, and global and medial temporal lobe atrophy are associated with increased risk of
PSD [32]. Dementia is severe in lesions involving thalamus or midbrain. After stroke, recov‐
ery of patient involving both physical and cognitive functions is variable.
2.2.2. Multi-infarct dementia
As the name suggests, there are multiple strokes occurring in the same patient (Figure 2).
Sometimes these may even go undetected and may be noticed only after a major stroke. This
causes the characteristic step-wise progression of the disease where there may be deteriora‐
tion in cognitive abilities but also there may be periods of stability or even improvement of
the patient. The severity of dementia increases with each stroke. The type of vessel involved
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may be either large or small vessels or both. It is thought that the reason for multiple infarcts
is due to underlying predisposing factors associated with VaD.
 
Figure 1. Brain MRI scan (DWI sequences) of a 59 years old man presenting with an acute onset of confusion, ideative
and motor slowness and apathy with memory loss. A marked cognitive and motor slowness and apathy remained af‐
ter 15 days from onset. MRI scan showed ischemic lesions in the medial part of both thalami and in the midbrain (top
of the basilar syndrome).
2.2.3. Binswanger’s disease
It is a type of subcortical ischaemic VaD. It is a progressive small vessel disease. Occlusion
of small arteries (arterioles) leads to hypoperfusion and this in turn leads to white matter
lacunes and necrosis [33]. Clinical features vary slightly where the patients develop a slowly
progressing dementia. Brain imaging studies reveal increased white matter and periventric‐
ular lesions (Figure 3).
 
Figure 2. Brain MRI (FLAIR sequences) of a 80 years old man with a multi-infarct progressive dementia with bulbar
symptoms. Multiple cortical and subcortical infarct are seen together with periventricular white matter changes and
corticola atrophy.
Other Dementias
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 Figure 3. White matter changes and periventricular lesions observed in a 82 years old man with loss of memory and
slowly progressive cognitive impairment. Brain atrophy is also present (mixed dementia)
2.2.4. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and
Leukoencephalopathy (CADASIL)
CADASIL is a familial form of vascular dementia. It is associated with migraine and is a
subcortical ischaemic type of dementia. It is due to mutation in the NOTCH3 gene on chro‐
mosome 19. It is the most common genetic form of VaD. The disease has an autosomal dom‐
inant type of inheritance. From the pathological point of view vascular lesions occur not
only in vessels of the brain but also other organs. Hence, it can be diagnosed by skin biopsy
and confirmed by immunohistochemistry with NOTCH3 monoclonal antibody [34]. Brain
imaging shows white matter lesions of necrosis and lacunae. A recessive form has also been
described and mutations in the HTRA1 gene identified [35,36].
2.3. Neuropathology
The types of lesions seen in VaD are mainly infarctions. The infarctions may be present
in  the  cortex  and subcortical  regions  (complete  infarctions)  as  well  as  the  white  matter
and  basal  ganglia  (lacunar  infarctions).  Cerebral  amyloid  angiopathy  may  be  observed.
Atrophy  and  sclerosis  of  hippocampus  are  also  common  [37].  A  study  was  conducted
on  135  post-mortem brains  with  dementia  to  conceptualize  the  natural  history  of  cere‐
brovascular  lesions  (CVL)  and  operationalize  it  into  a  cerebrovascular  staging  system
[38]. The authors rated the following CVL; in the frontal and temporal lobes: arterioscle‐
rosis,  amyloid angiopathy,  perivascular  hemosiderin  leakage,  perivascular  spaces  dilata‐
tion  in  deep  and  juxtacortical  white  matter,  myelin  loss  and  cortical  infarcts;  in  the
hippocampus:  neuronal  loss,  perivascular  spaces  dilatation  and  presence  of  micro-  and
large infarcts; in the basal ganglia: arteriosclerosis, perivascular spaces dilatation, density
of micro- and large infarcts, either lacunar or territorial.
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2.4. Management
2.4.1. Investigations
Routine blood investigations and biochemistry including lipid and glucose levels as well as
liver enzymes must be done in order to rule out treatable causes of dementia and identify
risk factors such as hyperlipidemia and diabetes. The Mini-Mental State Examination is a
brief but good way of screening for dementia. Executive function may be tested by Clock-
Drawing Task. A proper history from the patient and/or informant must be obtained and
should include history for unprovoked falls, TIA and urinary incontinence also. Computed
tomography (CT) and Magnetic Resonance Imaging (MRI) are useful investigations to check
for both large and small infarcts and white matter lesions. Other imaging techniques like
Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomogra‐
phy (PET) may be done to assess blood flow. Population MRI studies have revealed high
prevalence of overt small-vessel disease in the elderly population (23 % for silent lacunes
and 95 % for incidental hyperintensities). These lesions are associated with an increased risk
for stroke and dementia [39]. A thorough and complete neurological examination must be
done to confirm signs of stroke. It is extremely important to conduct a good cardiovascular
examination including measuring blood pressure and examining for presence of murmurs.
Electrocardiogram to look for presence of fibrillation is essential.
2.4.2. Treatment
Since there are several risk factors associated with developing VaD, it is important to treat
them or keep them in check. In people at risk for VCI, smoking cessation is mandatory. Life‐
style modification such as eating a low-fat diet, moderation in alcohol intake and regular ex‐
ercise are reasonably effective. Hypertension, hyperglycemia and hypercholesterolaemia
must be treated. Antiplatelet therapy is used and is effective in preventing further strokes.
Primary prevention with antihypertensive drugs perindopril and indapamide has been
shown to be effective in reducing risk of dementia and cognitive decline in patients with re‐
current stroke [40]. Treatment of VaD is usually symptomatic. No specific drug has yet been
recommended. Cholinesterase inhibitors (ChEI) such as donepezil have been found to be
beneficial in improving cognition [41] but other ChEI such as galantamine[42] and rivastig‐
mine [43] have been found to be ineffective. N-methyl-D-aspartate antagonist like meman‐
tine has been tried in trials but was also found to be ineffective [44].
2.5. Prognosis
The prognosis of VaD is generally poor. Most patients die within few years from onset.
Death may be due to CVD or complications of dementia. Since there is no specific treatment
recommended, it is very important to diagnose the disease at an early stage and stop it from
progressing further. Preventive measures are also vital.
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3. Dementia with lewy bodies
Dementia with Lewy Bodies (DLB) is a degenerative type of dementia (like AD). It is the sec‐
ond most common type of degenerative dementia (after AD). Lewy Bodies are inclusion
bodies present in the cytoplasm containing a protein called ubiquitin. The first cases of DLB
with cortical involvement were reported in 1961 [45]. The Lewy Body was seen in autopsy
by neuropathological staining only as far as 1989 [46]. Over the years, DLB has been given
several terminologies, namely diffuse Lewy body Disease [47], Lewy body dementia [48],
Lewy body variant of AD [49], senile dementia of Lewy body type [50] and dementia associ‐
ated with cortical Lewy bodies [51].
3.1. Epidemiology
The prevalence of DLB is about 0.1 to 5 % in the general population and about 10 to 20 % of
all dementia cases [52-54]. The incidence is about 0.1 % a year in the general population and
about 3 % a year of all new dementia diagnosed cases [55]. A French cohort study found that
the incidence of DLB increases with age [56].
3.2. Clinical features and pathophysiology
The main feature is the presence of dementia which means impairment of cognition affect‐
ing normal day to day and social activities. Guidelines [57] suggest the core features as be‐
ing fluctuation in level of cognition, detailed visual hallucinations that are recurrent and
parkinsonism that is spontaneous. Any two of these core features indicate probable DLB
while the presence of only one of the core features indicates possible DLB. Other psychiatric
features may include depression, anxiety or apathy. There may also be a history of repeated
falls given by the carers. Another interesting feature is the presence of Rapid Eye Movement
sleep behaviour disorder (RBD) [58, 59]. RBD is a sleep disorder and is characterized by loss
of muscle atonia during rapid eye movement as well as movement of limbs, with or without
vocalization and dreaming. Carers often give a history that it is as though the patient is act‐
ing out his or her dreams. A recent study [60] found that inclusion of RBD as a core feature
may help improve diagnosis of DLB.
On pathological  examination,  LB contain ubiquitin which is  examined by immunohisto‐
chemistry. Increased presence of LB in the parahippocampus has been linked to increase
in the severity of dementia [61].  DLB patholgy has been shown to be related to plaques
in hippocampus and amygdala [62]. Another biomarker for diagnosis is α-synuclein (AS)
immunohistochemistry  [63].  Genetic  mutation of  AS has  also  been associated with DLB
[64].  Diagnosis with AS staining was found to be more sensitive and more specific than
ubiquitin staining [65].  Presence of LB in the temporal lobe has been shown to be relat‐
ed to visual hallucinations [66].
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3.3. Management
3.3.1. Investigations
Clinically, dementia must be diagnosed. Other neuropsychiatric features such as depression,
hallucinations and sleep disturbances must be identified. Proper history from carer or fami‐
ly member must be obtained. A complete psychiatric and neurological evaluation must be
carried out. There are no specific diagnostic tests. MRI may show preservation of medial
temporal lobe [67] or reduced amygdala volume [62]. SPECT may show hypoperfusion in
occipital lobe [68]. Using SPECT with dopamine transporter imaging is turning out to be
promising [69,70]. Imaging and findings of global amyloid deposition may also give a clue
in diagnosis of LBD [71].
3.3.2. Treatment
Drugs used in treatment include levodopa viz. usually used to treat Parkinson’s disease. A
one year follow-up study has shown it to be acutely effective [72] but its use is debatable as
it also lead to adverse effects most notably being hallucinations [73]. Another promising
drug is memantine which was also found to be well tolerated [74]. A Cochrane review
found cholinesterase inhibitors to be not useful in patients with DLB [75]. Other measures
include education of carers and also reality orientation of patients.
3.4. Prognosis
The prognosis in DLB can be variable. Initial health and well-being may play a role in decid‐
ing the prognosis. When compared to AD, the prognosis has been found to be similar [76] as
well as more severe [77]. No single factor have been identified that may dictate the outcome
of disease progression [78].
4. Frontotemporal dementia
Frontotemporal dementia (FTD) is considered to be the second most common type of early-
onset (before the age of 65) dementia. There is pathological involvement of frontal and tem‐
poral lobes of the brain. FTD consists of a behavioural variant (bvFTD) and a language
variant. The language variant can be further divided into semantic dementia (SD) and pro‐
gressive non-fluent aphasia (PNFA). Overlap of FTD with motor neuron disease (MND) is
also seen clinically, pathologically and genetically [79]. The whole clinico-pathological spec‐
trum is often referred to as frontotemporal lobar degeneration.
4.1. Epidemiology
The prevalence of FTD was found to be about 15 in 100,000 in UK involving age groups
45-64 years [80] while in the Netherlands it was found to be 9.4 per 100,000 in the age group
60-69 years [81]. The prevalence of early-onset AD and FTD was (be consistent between past
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and present verbs) found to be similar [80,82]. The incidence was found to be about 3.5 cases
per 100000 person-years [83]. Average age of onset is around 50-60 years [80,81].
4.2. Clinical Features and pathophysiology
The core features are an insidious onset, decline in personal and social conduct as well as
early emotional blunting and loss of insight [84]. The most common presenting symptoms
are then changes in behaviour. Decrease in cognitive functions involving executive functions
and speech is also observed. bvFTD is the most common of the subtypes [85] and is consid‐
ered to be the most typical of FTD. It is associated with degeneration of frontal and temporal
lobes [86] Other important features include behavioural disinhibition, apathy and loss of
empathy [87]. SD is characterised by loss of ability to name and recognise words, objects and
faces. It is associated with atrophy of left temporal lobe [88]. However, at least initially,
speech in SD may be unhampered, fluent and grammatically correct [89]. In PNFA, speech
is hampered and is grammatically incorrect but usually comprehension is preserved. This is
associated with problems in language expression [89] and also with left temporal lobe atro‐
phy and Broca’s area degeneration [84,90]. FTD associated with MND has similar clinical
presentations involving areas of language, memory and behavioural changes[91]. Genetic
studies involving families where some members have FTD and others have MND have
shown a repeat of hexanucleotide sequence GGGGCC in chromosome 9 open reading frame
72 region (C9ORF72) [92,93].
FTLD shows atrophy or degeneration of frontal and/or temporal lobes along with microva‐
cuolation and neuronal loss in the cerebral cortex [94]. By the use of immunohistochemistry,
FTLD is associated with the accumulation of microtubule-associated protein tau and trans‐
active response DNA-binding protein 43 (TDP-43). It can also be divided into two types (1)
FTLD with tau-positive inclusions (FLTD-tau) and (2) FTLD with ubiquitin-positive and
TDP-43-positive but tau-negative inclusions (FLTD-TDP) [95]. FLTD-tau mainly present as
PNFA and overlap with Pick’s disease while FLTD-TDP present mainly as SD and is associ‐
ated with MND. Patients with bvFTD can show either of the two types of pathology [96,97].
Apart from TDP-43 involvement in MND, another protein called fused in sarcoma (FUS) is
also associated with familial cases of dementia and MND [98].
4.3. Management
4.3.1. Investigations
MRI is the most useful investigation. Features of lobar atrophy may be observed. In bvFTD,
there is involvement of frontal, temporal, cortical and subcortical areas (Figure 4). Hypoper‐
fusion of these areas is also seen with SPECT and hypometabolism with PET. In the lan‐
guage variant, left temporal grey matter involvement is observed. Orbitofrontal cortex
involvement is associated with behavioural changes in these patients. Also, cortical and sub‐
cortical hyoperfusion is found to be more marked on the left side [99]. A complete neuro‐
psychological battery is necessary to fully characterise clinically these patients.
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 Figure 4. MRI brain scan (FLAIR and T2 sequences) of a 75 old woman with progressive FTD with mainly behavioural
disturbances showing frontal and temporal lobe atrophy along with minor periventricular hyperintensities. She had
deficit in executive and attention functions, aggressive behaviour and obsessive-compulsive disorder.
4.3.2. Treatment
No known or effective treatment exists for FTD. Treatment is mainly supportive or pallia‐
tive. Multi-disciplinary management involving psychiatrist, physician, clinical psychologist
and specialist nurse may be an effective way to treat patients with FTD.
4.4. Prognosis
The prognosis  varies  and to  some extent  depends  on  the  type  of  FTD.  The  severity  of
the  disease  is  more  and  clinical  progression  is  faster  in  bvFTD  [100].  In  the  language
variant, the disease progression is slow with mainly impairment of language component
for several years [89].
5. Dementia in other diseases
5.1. Dementia in Pick’s disease
Pick’s disease (PD) is a neurodegenerative disease. From the clinical point of view it over‐
laps with FTD but it is characterised by the presence of Pick bodies. These Pick bodies are
argyrophilic, intraneuronal, cytoplasmic inclusions made up of three-repeat tau. Other fea‐
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tures include circumscribed atrophy of frontal and temporal lobes, gliosis and loss of neu‐
rons [101] as it has seen in FTD. Clinically, patients present with symptoms similar to FTD
such as those of bvFTD, PNFA and SD as mentioned previously. Therefore, it is difficult to
distinguish FTD from PD clinically. Post-mortem clinical correlation studies have shown
that PD is associated more closely with behavioural and language associated symptoms and
not with motor disturbances [102]. The age of onset is around 45 to 65 years [103, 104]. There
are no known risk factors associated with PD. ‘Knife-edge’ atrophy is observed pathological‐
ly in the cortex which implies sharp, circumscribed degeneration (also referred to as ‘dried
walnut’ appearance) [105]. There may also be the presence of swollen, ballooned neurons in
the cortex called as Pick cells although they are not always present. No specific treatment is
available at present for PD.
5.2. Dementia in Creutzfeldt-Jakob disease
Creutzfeldt-Jakob disease (CJD) is a subacute fatal neurodegenerative disease. It is the most
common of the prion diseases to affect humans. Prion proteins are infectious-like agents that
cause diseases termed as transmissible spongiform encephalopathies. Prion proteins are
found normally in the cells of central nervous system and immune system [106]. However, a
misfolded form of this protein is considered to be pathologic. CJD occurs as sporadic, genet‐
ic, iatrogenic or juvenile variant forms. Clinical features associated with CJD are a rapidly
progressive encephalopathy with dementia, cerebellar ataxia and myoclonus [107]. It pro‐
gresses to stupor and coma in few months. The sporadic form of CJD (sCJD) accounts for
about 85 % of all CJD cases [108, 109]. The average age of onset is around 60 years. Median
time to death is about 5 months and 85-90 % of patients die within 1 year of onset [110-112].
In the familial form, mutations in the gene PNRP that encodes the prion protein are seen.
Autosomal dominant inheritance is observed. Disease progression is slower than sCJD. Ia‐
trogenic form of CJD occurs accidently during surgical or medical procedures. In the juve‐
nile variant form of CJD (vCJD), the age of onset is around 30 years. Other features include
early psychiatric features (depression, anxiety, apathy), delay in dementia and duration of
illness of more than 6 months [113,114]. Pathologically all cases of CJD have features of neu‐
ronal loss, spongiform changes (vacuolation in grey matter) and astrogliosis [107]. Patholog‐
ical prion proteins can be observed via immunohistochemistry [113].
5.3. Dementia in Huntington’s disease
Huntington’s disease (HD) is a genetic cause of dementia. It is inherited as an autosomal-
dominant trait. The mutation in the huntingtin gene (chromosome 4) producing the disease
was identified in 1993 [115]. Mutant protein called huntingtin has an abnormal CAG repeats
(at least 36) on the coding sequence of this gene. HD is characterised by chorea (involuntary,
jerky movement of limbs spreading to all muscles of body), behavioural and psychiatric
changes (mainly psychoses and depression) along with dementia. The onset is around mid‐
dle age (about 40 years). Cognitive changes mainly slowing of intellectual capabilities and
decline of executive functions occur and may sometimes be detected even before onset of
motor symptoms [116, 117]. Dementia is progressive and increases as the course of the dis‐
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ease advances. Pathological features include neostriatal (caudate and putamen) atrophy in
early stages of disease [118] and presence of intranuclear inclusions of mutant huntingtin in
neurons of the striatum region of the brain [119]. Management includes genetic counselling,
regular neurological and neuropsychiatric evaluation. Treatment is mainly symptomatic.
5.4. Dementia in Parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disease mainly associated with motor
symptoms. However, dementia develops in about 40 % of the sufferers [120,121]. Dementia
developing after diagnosis of PD is termed as Parkinson’s disease dementia (PDD). The
prevalence of PDD in PD after 8-10 years has been found to be nearly 75 % [122,123]. Risk
factors for developing early dementia are old age and severity of motor symptoms [123].
Clinical diagnostic features associated with PDD are impairment in attention, executive
functions and memory. Other behavioural features are apathy, hallucinations and delusions
[124]. Sleep disorders like RBD may be present and has been found to be associated with
increased risk of developing PDD [125]. There are no investigations to diagnose PDD but
there is association with hippocampal and medial temporal lobe atrophy [126]. SPECT stud‐
ies have found abnormalities in dopamine transporter and occipital region hypoperfusion
[127]. Cholinergic deficits are also observed and treatment with cholinesterase inhibitors has
been found to be useful in PDD [128]. Treatment is otherwise symptomatic. Prognosis varies
but PDD sufferers have been found to have increased risk of mortality [129].
5.5. Dementia in HIV disease
The HIV-1 virus is known to cause AIDS and also other neurological disorders. These neu‐
rological disorders are known as HIV-associated neurocognitive disorders (HAND). The
most severe form of HAND is HIV-associated dementia (HAD) [130]. The annual incidence
of HAD in 1990’s was 7 % [131]. However, with the advent of highly active antiretroviral
therapy (HAART), the incidence has decreased by more than half to about 2 to 4% [132-134].
The clinical features as part of the diagnostic criteriae include dementia, no evidence for
presence of delirium nor any other cause for dementia [130]. Neuroinflammation in brain is
observed. Viral proteins that are released from infected glial cells activate uninfected micro‐
glial cells and astrocytes to secrete cytokines and neurotoxins. This causes neuronal cell
death i.e. neurodegeneration [135,136]. To help in detecting HAD, a rating scale has been de‐
veloped which tests timed fingertapping, alternating hand sequence test and recall of four
items at 2 minutes [137]. HAART is used as treatment of HAD. The aim is to suppress the
virus and its replication in plasma and CNS [138]. Some of the drugs used in HAART regi‐
men are a combination of efavirenz, lamivudine and zidovudine. Other medications like
memantine, valproic acid and selegiline listed under adjunctive therapies have not been
found to be useful in HAD [139]. HAD is associated with increased mortality with median
survival time after dementia found to be 6 months [131].
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6. Conclusions
The NAD or other dementias form a vital part of the fight against dementia and its conse‐
quences. Even though AD forms the bulk of dementia cases, knowledge and understanding
of NAD might play an important role in the much needed quest for cure or prevention of
dementia. More cutting-edge research into these diseases and their pathogenesis will help
combat the spread and probably even onset of dementia.
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